2017
DOI: 10.23822/eurannaci.1764-1489.22
|View full text |Cite
|
Sign up to set email alerts
|

New therapeutic approach by sirolimus for enteropathy treatment in patients with LRBA deficiency

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
18
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 32 publications
(18 citation statements)
references
References 23 publications
0
18
0
Order By: Relevance
“…Individualized medications (anti‐inflammatory and immunosuppressive drugs, biological agents, and monoclonal antibody) used for autoimmune and inflammatory complications in patients with LRBA deficiency are shown in Supporting Information Table S4. Sirolimus was the last therapeutic approach for management of enteropathy in six patients (Azizi, Abolhassani, Yazdani, et al, ). Although LRBA‐deficient patients who received “monoclonal antibody, immunosuppressive and/or biological agents” had lower lymphocyte counts than other patients (median [IQR]: 2000 [1720–3300 vs. 2400 [2370–3800] cell/µl; p = 0.212), no difference was noted between the frequency of CD4 + T cells in LRBA‐deficient patients who received this type of therapy and those who did not (median [IQR]: 23.80 [7.17–46.10] vs. 28.85 [18.22–45.25]; p = 0.775).…”
Section: Resultsmentioning
confidence: 99%
“…Individualized medications (anti‐inflammatory and immunosuppressive drugs, biological agents, and monoclonal antibody) used for autoimmune and inflammatory complications in patients with LRBA deficiency are shown in Supporting Information Table S4. Sirolimus was the last therapeutic approach for management of enteropathy in six patients (Azizi, Abolhassani, Yazdani, et al, ). Although LRBA‐deficient patients who received “monoclonal antibody, immunosuppressive and/or biological agents” had lower lymphocyte counts than other patients (median [IQR]: 2000 [1720–3300 vs. 2400 [2370–3800] cell/µl; p = 0.212), no difference was noted between the frequency of CD4 + T cells in LRBA‐deficient patients who received this type of therapy and those who did not (median [IQR]: 23.80 [7.17–46.10] vs. 28.85 [18.22–45.25]; p = 0.775).…”
Section: Resultsmentioning
confidence: 99%
“…In our case, sirolimus had been used with partial benefit on the ALPS-like lymphoproliferation, even if previous reports showed promising results (34). Only abatacept allowed a consistent and persistent improvement of the gastritis, allowing weaning from glucocorticoids and proton pump inhibitors.…”
Section: Discussionmentioning
confidence: 75%
“…Sirolimus is well known for its effectiveness in treating autoimmune cytopenias [29, 30]. Azizi et al described the use of sirolimus for multiple drug resistant LRBA enteropathy [31]. Our patient’s life-threatening hemolytic anemia responded rapidly to sirolimus, although she did develop other autoimmune manifestations years later requiring additional therapies.…”
Section: Discussionmentioning
confidence: 80%